381 related articles for article (PubMed ID: 37876546)
1. SIRT6's function in controlling the metabolism of lipids and glucose in diabetic nephropathy.
Wang Y; Liu T; Cai Y; Liu W; Guo J
Front Endocrinol (Lausanne); 2023; 14():1244705. PubMed ID: 37876546
[TBL] [Abstract][Full Text] [Related]
2. The many faces of SIRT6 in the retina and retinal pigment epithelium.
Cheng J; Keuthan CJ; Esumi N
Front Cell Dev Biol; 2023; 11():1244765. PubMed ID: 38016059
[TBL] [Abstract][Full Text] [Related]
3. Chrysin improves diabetic nephropathy by regulating the AMPK-mediated lipid metabolism in HFD/STZ-induced DN mice.
Zhou Y; Tao H; Xu N; Zhou S; Peng Y; Zhu J; Liu S; Chang Y
J Food Biochem; 2022 Dec; 46(12):e14379. PubMed ID: 35976957
[TBL] [Abstract][Full Text] [Related]
4. Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6.
Wang Z; Wu Q; Wang H; Gao Y; Nie K; Tang Y; Su H; Hu M; Gong J; Fang K; Dong H
Phytomedicine; 2022 Sep; 104():154276. PubMed ID: 35728388
[TBL] [Abstract][Full Text] [Related]
5. Sirtuin 6, a possible therapeutic target for type 2 diabetes.
Bae EJ
Arch Pharm Res; 2017 Dec; 40(12):1380-1389. PubMed ID: 29177584
[TBL] [Abstract][Full Text] [Related]
6. Lipophagy: A Potential Therapeutic Target for Diabetic Nephropathy.
Yang M; Song P; Zhao L; Wang X
Curr Med Chem; 2023; 30(16):1875-1886. PubMed ID: 35894456
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte Sirtuin 6 Protects against Atherosclerosis and Steatohepatitis by Regulating Lipid Homeostasis.
Zhu Y; Hu S; Pan X; Gopoju R; Cassim Bawa FN; Yin L; Xu Y; Zhang Y
Cells; 2023 Aug; 12(15):. PubMed ID: 37566087
[TBL] [Abstract][Full Text] [Related]
8. Lipidomics Reveals Serum Specific Lipid Alterations in Diabetic Nephropathy.
Xu T; Xu X; Zhang L; Zhang K; Wei Q; Zhu L; Yu Y; Xiao L; Lin L; Qian W; Wang J; Ke M; An X; Liu S
Front Endocrinol (Lausanne); 2021; 12():781417. PubMed ID: 34956093
[TBL] [Abstract][Full Text] [Related]
9. Sirt6 enhances macrophage lipophagy and improves lipid metabolism disorder by regulating the Wnt1/β-catenin pathway in atherosclerosis.
Wang T; Cheng Z; Zhao R; Cheng J; Ren H; Zhang P; Liu P; Hao Q; Zhang Q; Yu X; Sun D; Zhang D
Lipids Health Dis; 2023 Sep; 22(1):156. PubMed ID: 37736721
[TBL] [Abstract][Full Text] [Related]
10. Emerging roles of SIRT6 in human diseases and its modulators.
Liu G; Chen H; Liu H; Zhang W; Zhou J
Med Res Rev; 2021 Mar; 41(2):1089-1137. PubMed ID: 33325563
[TBL] [Abstract][Full Text] [Related]
11. Association of SIRT6 circulating levels with urinary and glycometabolic markers in pre-diabetes and diabetes.
Bian C; Gao J; Wang Y; Li J; Luan Z; Lu H; Ren H
Acta Diabetol; 2021 Nov; 58(11):1551-1562. PubMed ID: 34148121
[TBL] [Abstract][Full Text] [Related]
12. Identifying the functional contribution of the defatty-acylase activity of SIRT6.
Zhang X; Khan S; Jiang H; Antonyak MA; Chen X; Spiegelman NA; Shrimp JH; Cerione RA; Lin H
Nat Chem Biol; 2016 Aug; 12(8):614-20. PubMed ID: 27322069
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Role of SIRT7 in Glucose and Lipid Metabolism.
Yamagata K; Mizumoto T; Yoshizawa T
Cells; 2023 Dec; 13(1):. PubMed ID: 38201252
[TBL] [Abstract][Full Text] [Related]
14. CircRNA circ-ITCH improves renal inflammation and fibrosis in streptozotocin-induced diabetic mice by regulating the miR-33a-5p/SIRT6 axis.
Liu J; Duan P; Xu C; Xu D; Liu Y; Jiang J
Inflamm Res; 2021 Jul; 70(7):835-846. PubMed ID: 34216220
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase SIRT6: at the crossroads between epigenetics, metabolism and disease.
Etchegaray JP; Zhong L; Mostoslavsky R
Curr Top Med Chem; 2013; 13(23):2991-3000. PubMed ID: 24171769
[TBL] [Abstract][Full Text] [Related]
16. FOXO3a Protects against Kidney Injury in Type II Diabetic Nephropathy by Promoting Sirt6 Expression and Inhibiting Smad3 Acetylation.
Wang X; Ji T; Li X; Qu X; Bai S
Oxid Med Cell Longev; 2021; 2021():5565761. PubMed ID: 34122724
[TBL] [Abstract][Full Text] [Related]
17. Effect of siglidine on glucose lipid metabolism and the expression of iNOS and GLP-1 receptors in diabetic rats.
Zhang HY; Li Y; Zhong YH; Ruan LB; Yang TR; Yin HP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8984-8989. PubMed ID: 30575943
[TBL] [Abstract][Full Text] [Related]
18. SIRT6: A potential therapeutic target for diabetic cardiomyopathy.
Wu T; Qu Y; Xu S; Wang Y; Liu X; Ma D
FASEB J; 2023 Aug; 37(8):e23099. PubMed ID: 37462453
[TBL] [Abstract][Full Text] [Related]
19. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy.
Kitada M; Kume S; Takeda-Watanabe A; Kanasaki K; Koya D
Clin Sci (Lond); 2013 Feb; 124(3):153-64. PubMed ID: 23075334
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model.
Sociali G; Magnone M; Ravera S; Damonte P; Vigliarolo T; Von Holtey M; Vellone VG; Millo E; Caffa I; Cea M; Parenti MD; Del Rio A; Murone M; Mostoslavsky R; Grozio A; Nencioni A; Bruzzone S
FASEB J; 2017 Jul; 31(7):3138-3149. PubMed ID: 28386046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
